Accelerating the development of new therapies
The companies currently hosted within the Institute span a wide range of sectors and technologies.
However they are all united by a common goal—improving patient care.
Skin cancer is the most common form of malignancy, with more individuals diagnosed each year than for all other cancers combined. For the last 150 years these malignancies have required an invasive biopsy for diagnosis, but Enspectra is leading a digital transformation in pathology by imaging real-time cellular anatomy in living tissue, without cuts or stains.
More than 110 million people worldwide suffer from non-healing, open wounds. High costs and overly complex technology severely limit, if not eliminate, access to advanced wound care technology. Healyx Labs is developing the lowest-cost and easiest-to-use wound vacuum technology for price-sensitive and underserved markets.
Over half a million patients with aging valves and vessels undergo structural repairs of the cardiovascular system each year. Though traditionally open surgeries have become less invasive, physicians are still faced with the challenge of closing large-bore access sites in the femoral artery. Lume is enabling safe and effective closure of these access sites to complement the growing incidence of large-bore endovascular procedures.
Approximately 50 percent of all women in the U.S. will suffer symptoms of a pelvic floor disorder resulting from childbirth by the time they turn 55, and over 20 million suffer from pelvic pain. Materna has developed two therapeutic dilation devices: the first is aimed at preventing maternal pelvic injuries during childbirth and shortening delivery time. The second is helping treat pelvic pain and dyspareunia.
Each day, more than 1,100 babies born in the U.S. require assistance breathing. MedicalCue has developed a bedside device that guides medical teams through newborn resuscitation, greatly increasing the accuracy of care delivered. The Cue platform analyzes vital patient information and determines the best path for patient care.
Each year, over 80 million people in the U.S. could benefit from Radial’s smart, wearable compression therapy system for the prevention of deep vein thrombosis, treating restless leg syndrome and healing venous leg ulcers. Radial’s intelligent compression technology combines best-in-class adjustable compression therapy, continuous monitoring, disease detection capability and digital patient engagement.